Liraglutide + canagliflozin combination aimed to prevent HGP rise, improve glycemic control in T2D.

Type 2 Diabetes (T2D) is characterized by impaired insulin secretion, insulin resistance, and elevated hepatic glucose production (HGP). While current therapies effectively lower blood glucose, many struggle to address the compensatory rise in HGP often seen with SGLT2 inhibitors like canagliflozin, which can blunt their overall efficacy. Combining agents that target different pathways, such as GLP-1 receptor (GLP-1R) agonists like liraglutide (improving insulin secretion and reducing glucagon) and sodium-glucose cotransporter 2 (SGLT2) inhibitors (increasing renal glucose excretion), offers a synergistic approach to achieve better glycemic control and broader cardiometabolic benefits. This study investigated whether this combination could specifically counteract the HGP increase.

This was a clinical trial (NCT01715428) enrolling 300 patients with Type 2 Diabetes. Participants received liraglutide 1.2 mg/daily in combination with canagliflozin. The study aimed to examine the effects of this combination therapy on several key parameters. Specific aims included preventing the increase in hepatic glucose production (HGP) following canagliflozin initiation, and achieving additive or synergistic effects on plasma glucose concentration, A1c, weight loss, reduction in hepatic and visceral fat content, and systolic/diastolic blood pressure, including 24-hour integrated blood pressure. The study design implies a comparison, likely against monotherapy or placebo, though not explicitly stated in the provided text.